Innovative approaches help recruit and retain patients in a rare disease hematology study

A sponsor contracted Fortrea to run its Phase III hematology study and enroll 250+ patients with a rare disease in a highly competitive therapeutic area. Learn how Fortrea implemented collaborative strategies to address recruiting challenges, maximize retention and reduce patient burden with digital health innovation.

Designing an optimal long-term follow- up program for gene therapies and genetically modified cell therapies

Optimizing clinical trials for pediatric obesity treatment

Incorporating the voice of patient in pediatric assent forms

Future-Proofing SaMD: Regulatory Strategies for Medical Software Development

The rise of software as a medical device (SaMD) is transforming healthcare by enabling real-time data analysis, personalized care and predictive diagnostics.

Implementing a critical infectious disease protocol

Detecting the Undetectable: The Rising Potential of Liquid Biopsies in Oncology

In the past decade, a vial of blood has become a powerful window into cancer biology. Liquid biopsies, once limited to detecting specific mutations in advanced lung cancer, now offer a dynamic, real-time view of tumor genetics across multiple cancer types.

Key challenges in pediatric vaccine trials in low- and middle- income countries

Low- and middle-income countries (LMICs) bear a disproportionate burden of infectious diseases, with 90% of preventable cases occurring in these regions.

Highlighting Fortrea’s commitment to advancing rare disease clinical research

Over the last 5 years, our team at Fortrea has supported more than 820 rare disease studies, each with its own challenges and complexities.

See how we navigated complexities in a Phase I ICU trial

Recent years have seen a growing need for advanced critical care solutions, driven by factors such as an aging population, emerging infectious diseases and increasingly complex medical interventions.